Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels

    Access Status
    Open access via publisher
    Authors
    McGuire, A.
    Urosevic, N.
    Chan, D.
    Dogra, G.
    Inglis, T.
    Chakera, Aron
    Date
    2014
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    McGuire, A. and Urosevic, N. and Chan, D. and Dogra, G. and Inglis, T. and Chakera, A. 2014. The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels. PPAR Research. 2014.
    Source Title
    PPAR Research
    DOI
    10.1155/2014/643189
    ISSN
    1687-4757
    School
    Curtin Medical School
    URI
    http://hdl.handle.net/20.500.11937/36790
    Collection
    • Curtin Research Publications
    Abstract

    © 2014 Amanda L. McGuire et al. Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk. The impact of renal impairment on cfDNA levels and whether cfDNA is associated with endothelial dysfunction and inflammation in CKD has not been systematically studied. We analysed cfDNA concentrations from patients with varying degrees of CKD. In addition, to determine whether there is a relationship between cfDNA, inflammation, and endothelial dysfunction in CKD, levels of proinflammatory cytokines and von Willebrand Factor (vWF) were measured in patients treated with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone or placebo for 8 weeks. cfDNA levels were not increased with renal impairment or associated with the degree of renal dysfunction (P = 0.5). Treatment with rosiglitazone for 8 weeks, but not placebo, was more likely to lead to a reduction in cfDNA levels (P = 0.046); however, the absolute changes in cfDNA concentrations during treatment were not statistically significant (P > 0.05). cfDNA levels correlated with markers of endothelial dysfunction (hsCRP P = 0.0497) and vWF (P = 0.0005). In conclusion, cell-free DNA levels are not influenced by renal impairment but do reflect endothelial dysfunction in patients with CKD.

    Related items

    Showing items related by title, author, creator and subject.

    • A cross-sectional study of the peripheral circulation in patients with nephrosis.
      Herrmann, Susan E. (2000)
      Background: Lipid abnormalities are a common feature of the nephrotic syndrome that is also characterised by oedema, hypoalbuminaemia, proteinuria, and hypercoagulability. Concern has arisen over the increased incidence ...
    • The current role for clinical and renal histological findings as predictor for outcome in Australian patients with lupus nephritis
      Nossent, J.; Raymond, W.; Kang, A.; Wong, D.; Ognjenovic, M.; Chakera, Aron (2018)
      © The Author(s) 2018. Objectives: To investigate the current demographic, clinical and histological characteristics of patients with lupus nephritis (LN) in Western Australia (WA) with regards to their predictive value ...
    • Elevated Osteoprotegerin Predicts Declining Renal Function in Elderly Women: A 10-Year Prospective Cohort Study
      Lewis, J.; Lim, W.; Zhu, K.; Wong, G.; Dhaliwal, Satvinder; Lim, E.; Ueland, T.; Bollerslev, J.; Prince, R. (2014)
      Background: Elevated osteoprotegerin (OPG) levels are inversely correlated with creatinine clearance and end-stage renal disease in patients with diabetes, however its role in predicting decline in renal function and ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.